GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-21| Trials & Approvals

Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations

by Richard Chau
Share To
According to a report recently released by the U.S. Food and Drug Administration (FDA), Biogen’s tofersen, an investigational drug for treating amyotrophic lateral sclerosis (ALS), is likely to show a clinical benefit on an aggressive form of the disease associated with rare mutations in superoxide dismutase 1 gene (SOD1). 

A Particularly Uncommon Form of an Already Rare Disease 

ALS is a progressive and fatal neurodegenerative disorder characterized by the destruction of motor neurons in the cerebral cortex, brain stem, and spinal cord, gradually leading to muscle atrophy and depriving patients of their ability to initiate and control voluntary movements. Most cases (approximately 90 - 95%) of ALS appear sporadically. In particular, mutations in the SOD1 gene exist in about 1-2% of patients (SOD1-ALS) without any traceable family history. The most common SOD1 gene mutations in North America are associated with younger age of onset and shorter survival, aggravating the already rare and devastating disease. 

Based on the figures cited by Biogen, an estimated 168,000 people are living with ALS globally, while SOD1-ALS affects approximately 330 people in the United States.



It's free! Log in now to read

LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top